As such, identification of Eomes+ CD4+ T cells as pathogenic lymphocytes in chronic CNS inflammation has a major implication in understanding the chronic CNS inflammation and designing a novel effective therapy for SPMS. This evidence concerns the gene CD4 and inflammatory response.